13/05/2024 – AB Science today announced that the European patent office has issued a Grant Decision for a patent relating to methods of treating severe mastocytosis with its lead compound masitinib Download PDF Post navigationPreviousPrevious post:A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patientsNextNext post:Annual financial results as of 31 December, 2023Related PostsSummary of the webcast held on January 28, 2025January 29, 2025Summary of the webcast held on December 16, 2024December 17, 2024AB Science webcast of December 16, 2024December 16, 2024Live webcast on Monday December 16, 2024, from 5.30pm to 6.30pm CETDecember 11, 2024AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell diseaseOctober 28, 2024AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALSOctober 17, 2024
AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell diseaseOctober 28, 2024
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALSOctober 17, 2024
